Latest Kaiser Health News Stories
Fentanyl and other painkillers marketed as safer than Purdue Pharma’s blockbuster drug left their own trail of overdose deaths.
The Trump administration signals it is willing to consider such a move if it is carefully tailored to focus solely on specific situations where a high-priced drug is made by one company.
With rising college costs, up to half of college students’ finances are stretched so tight they report that they were either not getting enough to eat or were worried about it, studies find.
A new government watchdog report outlines vulnerabilities in Medicare’s $17 billion hospice program, pointing to inadequate services, inappropriate billing and outright fraud.
After a USA Today Network-Kaiser Health News investigation, Medicare announced last week that it is re-evaluating whether these procedures “pose a significant safety risk” to patients.
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
Grants by top pharma group to lightly regulated, politically active nonprofits dwarf its conventional campaign spending.
Several major drugmakers vow to contain drug prices, but similar pledges since the 1990s have not had much impact.
After 130 years as a nonprofit with deep roots in western North Carolina, Mission Health announced in March that it was seeking to be bought by HCA Healthcare, the nation’s largest for-profit hospital chain.
KHN senior correspondent Sarah Varney reports on how the island’s mounting physician shortage is making it even more difficult to get care.
The average increase in California is smaller than the double-digit hikes expected around the nation, due largely to a healthier mix of enrollees and more competition in its marketplace. Still, health insurance prices keep growing faster than wages and general inflation.
Some California children with serious health care problems wait more than a year for wheelchairs, bath benches, commodes, specialized crutches and other crucial medical equipment. Critics blame the delays on a confusing bureaucratic maze of private insurers and public programs.
The vaccine, BCG, is relatively cheap. But experts caution the therapy could be overhyped and, if proven effective, wind up overpriced.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Margot Sanger-Katz of The New York Times, Anna Edney of Bloomberg News and Julie Appleby of Kaiser Health News discuss the health politics of the latest Supreme Court pick, as well as the Trump administration’s efforts to further undermine the Affordable Care Act. Plus, for extra credit, the panelists recommend their favorite health stories of the week.
Medicaid has struggled for years with poor oversight and billions lost to improper payments. A new report finds that despite their fraud-fighting rhetoric, Medicaid managed-care companies are not as rigorous as they should be in ensuring the integrity of the Medicaid payment system.
The Trump administration suspended a program over the weekend that helps stabilize the health insurance exchanges created by the Affordable Care Act, prompting some insurance companies to warn of higher premiums. KHN’s Julie Rovner and Chad Terhune explain the uncertain health care landscape in the U.S.
Other readers ask what can be done to challenge unexpected medical bills — whether the result of an emergency room visit or after a change in prescription drug coverage.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Stephanie Armour of The Wall Street Journal and Anna Edney of Bloomberg News discuss the latest enrollment numbers for the Affordable Care Act, Medicaid work requirements in Kentucky and President Donald Trump’s proposed government reorganization plan. Plus, for extra credit, the panelists recommend their favorite health stories of the week.
Efforts to provide care that integrates physical and mental health services are spreading, partly because untreated mental health conditions negatively affect physical health and escalate health care costs.
It’s getting increasingly difficult for patients to afford Truvada, also known as pre-exposure prophylaxis, or PrEP, because of the drug’s high price and insurance company efforts to restrict the use of coupons that shield patients from it.